Navigation Links
Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:1/29/2009

loyees," said Thomas B. King, Alexza President and CEO. "We are extremely grateful to all of our employees for their significant contributions and efforts to create new products with a new technology, which we believe have the potential to change the practice of medicine."

"We announced last October that we were significantly ahead of schedule with AZ-004, and at the same time, we would be prioritizing and focusing on what we believe are key near-term value-drivers in 2009, being critically aware of the very difficult capital markets," Mr. King continued. "Alexza has made substantial progress with its Staccato technology and product candidates over the past several years, but find our industry faced with an intensely difficult funding environment, which is critical to the growth of life science companies. The difficult choices we are making reflect that reality, even in the face of our own internal successes."

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive initial results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010. The Company has compl
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
9. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
10. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
11. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... CA (PRWEB) June 18, 2013 (PRWEB) June 18, ... #1 time and attendance system in North America, ... that shares employee data and payroll records between ... AccountLinx Plus automates ExakTime software setup and ... software imports employee data from a business’ current ...
(Date:6/18/2013)... Miami, FL (PRWEB) June 18, 2013 The ... associate the skin as an important human body part. Similar ... cared for in order to function, repair and grow. Recent ... with vitamins and supplements, is just as important as other ... and supplements to aid in skin cell reproduction, increase the ...
(Date:6/18/2013)... RegeneCure announced today the start of ... Regeneration (GBR) Dental Membrane as a bone stimulating aid for ... when patients have a tooth replaced with a dental implant ... implant. Consequently there is often a need to support the ... The bone substitute material, in turn, needs to be held ...
(Date:6/18/2013)... 2013 Edison Investment ... announces the initiation of full coverage of ... developing and marketing products for orphan oncology ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison has ... investment merits of BioAlliance Pharma, focusing in ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3
... March 18 Ingenuity Systems, the,leading provider ... has,announced that they have extended and expanded ... to Ingenuity Pathways Analysis,(IPA) software. The new ... to researchers for rapid assessment of the ...
... engineer genetic modifications, thereby providing scientists with a ... food production to drug discovery. However, this sophisticated ... threat of engineered pathogens. New research published in ... that computational tools could become a vital resource ...
... New Monograph Strengthens Safety Nets to Prevent Serious Health ... ... 17 The U.S. Pharmacopeial (USP),Convention today announced a ... official compendium of the United States. The,revision strengthens safety ...
Cached Biology Technology:Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline 2On the trail of rogue genetically modified pathogens 2USP Announces Revised Glycerin Monograph 2USP Announces Revised Glycerin Monograph 3
(Date:6/19/2013)... for human consumption qualifies as a gluten-free cereal that ... scientists have confirmed in a study published in ACS, ... , Joyce Irene Boye and colleagues point out that ... alone have CD. They develop gastrointestinal and other symptoms ... contain gluten-related proteins. Boye,s team sought to expand dietary ...
(Date:6/19/2013)... fall 2012, the European Medicines Agency (EMA) approved ... first ever gene therapy for clinical use in ... had developed AAV-LPL S447X for the treatment of ... deficiency (LPLD) which affects approximately one or two ... severe, life-threatening inflammations of the pancreas. Afflicted individuals ...
(Date:6/18/2013)... A UT Arlington environmental engineer has been awarded ... District to ensure water quality and flow in ... Project. , Andrew Kruzic, UT Arlington associate professor ... and locations to add monochloramine to the water ... the new pump stations and pipelines. Adding monochloramine ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2
... -- The number of overweight and obese Americans continues to ... up to 20 percent are obese. While the number of ... increase of overweight infants -- individuals under 11 months old ... pregnant women who are overweight/obese are more likely to give ...
... Elsevier announced today that it is launching a ... Engineering. The journal will be published bimonthly, and will ... of natural gas science and engineering. The first issue ... Natural Gas Science and Engineering will cover the fields ...
... Ohio State University have found that the number of copies ... cancer in a mouse model. Publishing in the Jan. 3 ... or Down syndrome in humans, can repress tumor growth. ... whether people with Down syndrome develop cancer less often than ...
Cached Biology News:Mom's obesity during conception phase may set the stage for offspring's obesity risk 2Mom's obesity during conception phase may set the stage for offspring's obesity risk 3Mom's obesity during conception phase may set the stage for offspring's obesity risk 4Elsevier launches new journal: Journal of Natural Gas Science and Engineering 2Gene dose affects tumor growth 2
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Request Info...
... epitope is specific for Kir2.1 and ... known protein.,SPECIES REACTIVITIES: The immunogen ... porcine and guinea pig. It is ... (17/19 residues) and chick (15/19 residues). ...
Biology Products: